Lisata Therapeutics Inc

LSTA06 Dec 2024
Healthcare
$2.73
-0.01 (-1.42%)
Lowest Today
$2.67
Highest Today
$2.77
Today’s Open
$2.73
Prev. Close
$2.74
52 Week High
$3.83
52 Week Low
$2.42
To Invest in Lisata Therapeutics Inc

Lisata Therapeutics Inc

Healthcare
LSTA06 Dec 2024
-0.01 (-1.42%)
1M
3M
6M
1Y
5Y
Low
$2.67
Day’s Range
High
$2.77
2.67
52 Week Low
$2.42
52-Week Range
52 Week High
$3.83
2.42
1 Day
-
1 Week
+1.83%
1 month return
-3.81%
3 month return
-7.66%
6 month return
-11.21%
1 Year return
+10.8%
3 Years return
-79.13%
5 Years return
-92.87%
10 Years return
-
Institutional Holdings
BML Capital Management LLC
3.39
Vanguard Group Inc
2.22
Vanguard Total Stock Mkt Idx Inv
1.52
Renaissance Technologies Corp
1.23
Vanguard Institutional Extnd Mkt Idx Tr
0.69
BlackRock Inc
0.67
Geode Capital Management, LLC
0.66

Market Status

Fundamentals
Market Cap
22.99 mln
PB Ratio
0.68
PE Ratio
0
Enterprise Value
-12.68 mln
Total Assets
54.69 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Organisation
Lisata Therapeutics Inc
Employees
25
Industry
Biotechnology
CEO
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step